

Survey of Statewide and Territorial Drug Court Coordinators

Practices and Policies Relating to Medication-Assisted Treatment for Opioid Use Disorders in Adult Drug Courts

Please provide your contact information:

State or Territory:

Name:

Title:

Phone:

Email:

The following questions pertain to **adult drug courts** in your state or territory. This may include hybrid adult drug courts that, for example, also serve persons charged with DWI or those with co-occurring disorders. It does **not** include stand-alone DWI courts, juvenile drug courts, family drug courts, veteran's treatment courts, mental health courts, or other types of treatment courts.

Responses will be reported in the aggregate and will **not** be attributed to any individual state or territory.

1. How many adult drug courts are there in your state or territory? _____
2. During the most recent 12 months, please rank-order the five (5) substances used most frequently by participants prior to entering your state or territory's adult drug courts (with 1 being the most frequent):

___ I am unsure of the five substances most frequently used by participants in my state's drug courts.

- ___ Alcohol
- ___ Marijuana
- ___ Pharmaceutical opioids (e.g., Oxycodone, Vicodin, codeine)
- ___ Heroin or other nonpharmaceutical opiates (e.g., opium)
- ___ Fentanyl (including carfentanyl)
- ___ Cocaine
- ___ Crack cocaine
- ___ Pharmaceutical sedatives (e.g., benzodiazepines, barbiturates)
- ___ Pharmaceutical stimulants (e.g., Ritalin, Dexedrine, Adderall)
- ___ Methamphetamine (e.g., "ice" or "crystal")
- ___ Synthetic cannabinoids (e.g., K2, Spice)
- ___ Hallucinogens (e.g., LSD, peyote, psilocybin mushrooms)
- ___ PCP (phencyclidine, Angel Dust)
- ___ Club drugs (e.g., MDMA, GHB)
- ___ Inhalants (e.g., model glue, aerosols)

Dextromethorphan (cough syrup)
 Other drugs (please describe) _____

3. Is this answer based on:

- Actual statewide or territorial data
 An informed estimate (e.g., based on individual program evaluations or data)
 Anecdotal information (e.g., reports or impressions of program coordinators)

4. During the past 12 months, approximately what percentage of adult drug court participants in your state or territory had a moderate to severe opioid use disorder? ____%.

- Unknown or Unable to answer
 Very few or None
 Some (about 25%)
 About half
 Most (about 75%)
 All or nearly all

5. Is this answer based on:

- Actual statewide or territorial data
 An informed estimate (e.g., based on individual program evaluations or data)
 Anecdotal information (e.g., reports or impressions of program coordinators)

6. Among your adult drug court participants with an opioid use disorder, what is the *primary* type of opioid problem seen?

- This information is not available
 Pharmaceutical opioids based on a legal prescription
 Pharmaceutical opioids without a prescription
 Illicit opioids (e.g., heroin, fentanyl, carfentanyl)

7. During the past 12 months, has there been a substantial change in the prevalence of opioid use among adult drug court participants in your state or territory? (please check all that apply)

- This information is not available
 Use of **pharmaceutical opioids** has **increased**
 Use of **pharmaceutical opioids** has **decreased**
 No apparent change in use of pharmaceutical opioids
 Use of **illicit opioids** has **increased**
 Use of **illicit opioids** has **decreased**
 No apparent change in use of illicit opioids

8. Approximately what proportion of adult drug courts in your state or territory offer some form of medication-assisted treatment (MAT) for participants with an opioid use disorder?

- Unknown or Unable to answer

- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

9. Does your state or territory have policies governing the use of MAT in adult drug courts?

Yes

No (skip to question 12)

Our state or territory is in the process of developing uniform policies governing the use of MAT in adult drug courts (skip to question 12)

Don't know (skip to question 12)

10. If yes, please respond to each policy listed:

	Yes	No	D/K
MAT is permitted only in limited cases, such as for the treatment of pregnant women			
All adult drug courts are required to receive formal training on MAT for opioid use disorders			
All adult drug courts are required to evaluate participants with opioid use disorders for their suitability for MAT			
Adult drug courts are required to permit participants to continue MAT previously prescribed for opioid use disorder			
Adult drug courts are permitted to begin MAT for new participants who have an opioid use disorder			
Adult drug courts are required to permit the use of naltrexone (e.g., Revia, Depade, Vivitrol) but not other medications such as buprenorphine or methadone			
Adult drug courts are prohibited from admitting participants receiving buprenorphine or methadone			
Adult drug courts require participants to taper or cease use of buprenorphine or methadone before graduating			

11. If your state or territory has uniform policies governing the use of MAT in adult drug courts, approximately how long ago were they enacted or most recently revised or updated?

Within the past year

In the past 1-2 years

3 or more years ago

Unknown or unable to answer

12. If MAT is available for participants in your state or territory's adult drug courts, approximately what proportion of adult drug courts include the following medications in their treatment regimens?

Not applicable; MAT is not available in our state or territory (please skip to question 19)

Methadone

Commented [DJA11]: Can you ask for a percentage? The way it reads is that you are giving them the options of 0, 25, 50, 75, 100%

Commented [EO2R1]: Percentages are now listed in parentheses for these options.

Commented [DJA3R1]: Thanks

Commented [EO4]: Original ONDCP Comment: Should this be – if response to above answer is No, then..... Perhaps these first two options should precede the table, as changed...

Commented [EO5R4]: Agree. Options have been adjusted to reflect this suggestion.

Commented [DJA6R4]: Thanks

Commented [EO7]: Original ONDCP Comment: Find the wording a bit confusing. Can you clarify what this statement is trying to capture? Is it for participants who after receiving a legal prescription for an opioid then become addicted? Or is it that judges were making people quit MAT to participate in drug courts? If that is the case, will this rewording work?

Commented [EO8R7]: We have broken the statement into two components to clarify: One for those clients that come into drug courts already on MAT and one for those who newl receive MAT once they enter the court.

Commented [DJA9R7]: Thanks

Commented [EO10]: We are referring to all naltrexone, not just previously prescribed.

Commented [DJA11]: Would the respondent skip to question 13? See comments for question 13 & 15.

Commented [EO12R11]: Respondents will now skip to question 19

Commented [DJA13R11]: Thanks

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Naltrexone (e.g., ReVia, Depade, Vivitrol)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

13. Approximately what proportion of adult drug courts in your state or territory have blanket policies or practices prohibiting use of the following medications by participants?

Methadone

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Naltrexone (e.g., ReVia, Depade, Vivitrol)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)

- About half
- Most (about 75%)
- All or nearly all

14. **We would like to know which medications are being used in drug courts to treat opioid use disorder.** In the past 12 months, approximately what proportion of adult drug court participants with an opioid use disorder received the following medications in your state or territory?

Methadone

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Naltrexone (e.g., ReVia, Depade, Vivitrol)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

15. Is this answer based on:
- Actual statewide or territorial data
 - An informed estimate (e.g., based on individual program evaluations or data)
 - Anecdotal information (e.g., reports or impressions of program coordinators)
16. Approximately what proportion of adult drug courts in your state or territory require participants to discontinue use of the following medications as a condition of graduating from the program?

Methadone

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)

Commented [DJA14]: Recommend adding preface for respondent to understand the nature of the question.

Commented [EO15R14]: This language applies to the entire survey, not just this one item. How about we put this language in the survey introduction?

Commented [DJA16R14]: Yes – that sound good.

All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Naltrexone (e.g., ReVia, Depade, Vivitrol)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

17. In the past 12 months, approximately what proportion of adult drug court participants with an opioid use disorder graduated from the program while still receiving the following medications?

Methadone

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Naltrexone (e.g., ReVia, Depade, Vivitrol)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

18. Is this answer based on:

- Actual statewide or territorial data
- An informed estimate (e.g., based on individual program evaluations or data)
- Anecdotal information (e.g., reports or impressions of program coordinators)

19. Approximately what proportion of adult drug courts in your state or territory **only** allow use of the following medications for pregnant women?

Methadone

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

Buprenorphine (e.g., Suboxone, Subutex, Zubsolv)

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

20. Approximately what proportion of your state or territory's adult drug courts have naloxone (Narcan, EVISIO) available onsite for participants experiencing an overdose?

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

21. Approximately what proportion of your state or territory's adult drug courts provide training to their participants on how to use naloxone (Narcan, EISIO) to reverse an overdose?

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

22. Approximately what proportion of your state or territory's adult drug courts provide naloxone kits to participants in their program?

- Unknown or Unable to answer
- Very few or None

- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

23. Is your state or territory considering expanding availability of MAT for opioid use disorders in adult drug courts?

- Not applicable; MAT is already used in all adult drug courts
- Not considering expansion
- Undecided on expansion [\(For more information on MAT - perhaps add link to pocket guides\)](#)
- Definitely considering expansion

24. To what extent do the views or opinions of personnel working in your adult drug courts hinder utilization of MAT?

- Not at all
- Slightly
- Moderately
- Greatly

25. To what extent do the views or opinions of external policy makers or administrators hinder utilization of MAT in your adult drug courts?

- Not at all
- Slightly
- Moderately
- Greatly

26. Please rank-order the top three (3) barriers that interfere with the use of MAT, or certain types of medications such as buprenorphine or methadone, in your state or territory's adult drug courts (with 1 being the most influential barrier):

- Not applicable; MAT is offered in all drug courts
- Refusal or disinterest from participants
- Philosophy of local treatment providers
- Insufficient funding
- Insufficient pool of qualified MAT providers
- Lack of knowledge of or familiarity with MAT by drug court staff
- Prohibitions from external (outside the drug court) policy makers or administrators
- Insufficient resources to prevent misuse or diversion (e.g., pill counts, observed ingestion)
- Insufficient access to training or technical assistance on MAT
- Use of other substances by participants that may interact dangerously with methadone or buprenorphine (e.g., benzodiazepines, alcohol)
- Other (please describe): _____

Commented [EO17]: We need to keep outside information separate from the survey. We also don't want to direct respondents away from the survey. We can send respondents the link to the pocket guides in the thank you email they will receive once they complete the survey.

Commented [DJA18R17]: Makes sense from a researcher's perspective. Obviously, hadn't considered. Thanks.

27. In the last 10 years, has your state or territory been subject to civil judgments or administrative penalties related to the delivery of MAT for treatment of opioid use disorder in the criminal justice system?

- Yes
- No
- Unknown or unable to answer
- Other – Please describe: _____

28. If yes, please describe:

29. Is your state or territory currently involved in pending or ongoing litigation related to the delivery or non-delivery of MAT for the treatment of opioid use disorders?

- Yes
- No
- Unknown or unable to answer

If yes, please describe:

30. In the past five years, have there been any funding mandates or mechanisms in your state or territory to expand the use of MAT in drug courts?

- Yes
- No
- Unknown or unable to answer

31. If yes, please describe:

32. In the past five years, have there been any changes in your state or territorial certification procedures for MAT providers?

- Yes
- No
- Unknown or unable to answer

33. If yes, please describe:

34. Approximately what proportion of adult drug courts in your state or territory received training to implement or improve delivery of MAT to participants?

- Unknown or Unable to answer
- Very few or None
- Some (about 25%)
- About half
- Most (about 75%)
- All or nearly all

35. Please briefly describe any MAT training received by your state or territory's adult drug courts:

36. If applicable, did this training help to expand the use of MAT or affect MAT practices in your state or territory's adult drug courts?

- Not applicable; no MAT training was received
- No
- A little
- Moderately
- Largely
- Unknown or unable to answer

37. Please briefly explain:

DRAFT

